Verve Therapeutics (VERV) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VERV Verve Therapeutics

Watchlist

6.580
-0.300-4.36%

Close Apr 24 16:00 ET

550.21MMarket Cap-2108P/E (TTM)

Pre-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
BenzingaApr 23 16:31 ET
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Stockhouse Apr 21 11:00 ET
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Verve Therapeutics, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating c
PR NewswireApr 19 10:30 ET
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
BenzingaApr 11 08:46 ET
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
TipRanksApr 8 06:25 ET
Top 10 Worst Performing Cathie Wood ARKK Holdings of 2024
Seeking AlphaApr 5 14:32 ET

Comments

y f ii

Apr 2 22:23

$Verve Therapeutics(VERV.US)$ 6

Trytosaveabit

Apr 2 19:13

Read the whole PR! But reason for fall

$Verve Therapeutics(VERV.US)$ However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...

Moomoo AI

Mar 3 21:23

Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.